Pyrrolidinedithiocarbamate (ammonium)

[1]Németh ZH, et al. Pyrrolidinedithiocarbamate inhibits NF-kappaB activation and IL-8 production in intestinal epithelial cells. Immunol Lett. 2003 Jan 2;85 (1) :41-6.|[2]Qin JD, et al. Effect of ammonium pyrrolidine dithiocarbamate (PDTC) on NF-κB activation and CYP2E1 content of rats with immunological liver injury. Pharm Biol. 2014 Nov;52 (11) :1460-1466.

Acta Pharm Sin B. 2022 Sep;12 (9) :3618-3638.|Acta Pharm Sin B. 2025 Mar;15 (3) :1535-1551.|Acta Pharmacol Sin. 2023 Aug;44 (8) :1712-1724.|Acta Pharmacol Sin. 2025 Aug;46 (8) :2163-2179.|Am J Cancer Res. 2023 Feb 15;13 (2) :419-435.|Am J Transl Res. 2018 Dec 15;10 (12) :4247-4257.|Andrology. 2023 Mar;11 (3) :575-590.|Ann Hepatol. 2024 Mar-Apr;29 (2) :101279.|Antivir Res. 2023 Feb 20;105559.|Aquaculture. 2025 Sep 15.|Arch Biochem Biophys. 2020 Feb 15;680:108242.|Biochim Biophys Acta Mol Basis Dis. 2023 Oct;1869 (7) :166819.|Biomed Pharmacother. 2019 Dec;120:109527.|bioRxiv. 2025 Aug 13:2025.08.11.669793.|BMC Microbiol. 2019 Jul 29;19 (1) :170.|Brain Behav Immun Health. 2022 Oct 29:26:100546.|Brain Behav Immun. 2020 Nov;90:108-137.|Brain Behav Immun. 2025 Oct:129:801-817.|Brain Res Bull. 2021 Dec:177:22-30.|Cancers (Basel) . 2023 Mar 6;15 (5) :1624.|Cell Death Dis. 2021 Jan 11;12 (1) :67.|Cell Death Dis. 2025 Apr 26;16 (1) :346.|Cell Death Dis. 2019 Feb 8;10 (2) :113. |Cell Rep Med. 2024 May 16:101580.|Cell Rep Med. 2025 Jan 16:101922.|Cell Signal. 2021 Nov:87:110137.|Cell Signal. 2024 Sep 18:111427.|Chem Biol Interact. 2022 Sep 25:365:110068.|Clin Transl Med. 2022 Jun;12 (6) :e850.|Cytokine. 2023 Feb:162:156086.|Dev Cell. 2025 Jun 23;60 (12) :1751-1767.e9.|Diabetes. 2024 Jun 13:db230969.|Dig Dis Sci. 2025 Aug 5.|EBioMedicine. 2024 Sep 16:108:105344.|EMBO Rep. 2021 Jul 5;22 (7) :e51678.|Evid Based Complement Alternat Med. 2021 Apr 1:2021:6662261.|Exp Biol Med. 2023 Feb;248 (4) :293-301.|Exp Eye Res. 2021 Apr:205:108507.|Eye Vis (Lond) . 2022 Sep 5;9 (1) :35.|FEBS Lett. 2021 Oct;595 (19) :2447-2462.|Food Biosci. 2021, 101268.|Front Cell Dev Biol. 2021 Feb 11:9:570451.|Gut Microbes. 2024 Jan-Dec;16 (1) :2313769.|Heliyon. 2023 Nov 20;9 (12) :e22599.|Hum Cell. 2023 Nov;36 (6) :1928-1937.|Inflammation. 2020 Jun;43 (3) :916-936. |Inflammation. 2021 Aug;44 (4) :1581-1591.|Int Immunopharmacol. 2019 May:70:28-36.|Int Immunopharmacol. 2020 Jan;78:106043.|Int Immunopharmacol. 2021 Jul:96:107779.|Int Immunopharmacol. 2023 Aug:121:110433.|Int Immunopharmacol. 2024 Sep 19;142 (Pt B) :113151.|Int Immunopharmacol. 2025 Aug 29:165:115451.|Int J Biol Macromol. 2022 Oct 21; S0141-8130 (22) 02401-1.|Int J Biol Sci. 2019 Jan 24;15 (3) :688-700.|Int J Biol Sci. 2025 Aug 11;21 (12) :5206-5222.|Int J Mol Sci. 2020 Dec 23;22 (1) :60.|Int J Mol Sci. 2021 Nov 11;22 (22) :12188.|Int J Mol Sci. 2023 Jul 11;24 (14) :11331.|Int J Oncol. 2020 Jan;56 (1) :101-112.|Int J Pharm. 2022 Nov 25:628:122361.|J Alzheimers Dis. 2022;85 (1) :167-178.|J Cell Physiol. 2019 Aug;234 (10) :18731-18747. |J Cell Physiol. 2019 Dec;234 (12) :23302-23314.|J Dairy Sci. 2023 Feb;106 (2) :1315-1329.|J Dairy Sci. 2024 Jul 19:S0022-0302 (24) 01027-0.|J Dairy Sci. 2025 Mar;108 (3) :2152-2168.|J Ethnopharmacol. 2023 Sep 15:313:116533.|J Exp Med. 2020 Jul 6;217 (7) :e20192083. |J Headache Pain. 2024 Jan 5;25 (1) :3.|J Headache Pain. 2025 May 1;26 (1) :97.|J Inflamm Res. 2021 Mar 5;14:719-735.|J Inflamm Res. 2021 Oct 5;14:5079-5094.|J Integr Neurosci. 2025 Jun 23;24 (6) :38100.|J Nanobiotechnology. 2025 Jul 5;23 (1) :488.|J Nat Prod. 2021 Apr 23;84 (4) :1022-1033.|J Neuroinflammation. 2021 Jun 28;18 (1) :146.|J Periodontal Res. 2024 Feb;59 (1) :140-150.|J Periodontol. 2025 Mar;96 (3) :255-267.|J Transl Med. 2025 Nov 13;23 (1) :1278.|J Virol. 2025 Aug 19;99 (8) :e0065525.|JACC Basic Transl Sci. 2022 Aug 3;7 (8) :820-840.|Lasers Med Sci. 2023 Oct 18;38 (1) :240.|Life Sci. 2025 Apr 23:123663.|Life Sci. 2025 Aug 22:380:123926.|Liver Int. 2022 Dec;42 (12) :2724-2742.|Mediators Inflamm. 2020 Jul 24;2020:8298615.|Microb Pathog. 2025 Apr 10:107559.|Microbiome. 2023 Jan 31;11 (1) :17.|Microorganisms. 2021 Sep 17;9 (9) :1983.|Mil Med Res. 2023 Nov 25;10 (1) :56.|Mol Immunol. 2022 Dec:152:67-77.|Mol Med Rep. 2020 Nov;22 (5) :4227-4235.|Mol Med. 2021 Dec 11;27 (1) :156.|Mol Med. 2023 Aug 21;29 (1) :113.|Mol Neurobiol. 2021 Aug;58 (8) :3848-3862.|Mol Neurobiol. 2022 Nov;59 (11) :6903-6917.|Nat Commun. 2024 Jan 10;15 (1) :449.|Nat Commun. 2024 Sep 12;15 (1) :7996.|Nat Commun. 2025 May 27;16 (1) :4887.|Neuropharmacology. 2025 Nov 15:279:110638.|Oncogene. 2022 Mar;41 (13) :1866-1881.|Oncoimmunology. 2018 Aug 23;7 (11) :e1461303. |Oncotarget. 2020 Feb;39 (7) :1414-1428.|Oxid Med Cell Longev. 2017:2017:3869561.|Oxid Med Cell Longev. 2021 Mar 29:2021:6678276.|Parasit Vectors. 2020 Aug 31;13 (1) :435.|Pathol Res Pract. 2025 Oct 17;276:156273.|Pharmaceuticals (Basel) . 2025 Jun 20;18 (7) :934.|Pharmacol Res. 2018 Jul:133:218-235.|Phytomedicine. 2022 Sep:104:154290.|Phytomedicine. 2025 Sep:145:157009.|Phytother Res. 2023 Oct;37 (10) :4771-4790.|PPAR Res. 2021 Aug 25:2021:6086265.|Redox Biol. 2021 Oct;46:102098.|Res Sq. 2025 Mar 16.|Research Square Preprint. 2021 Jan.|Research Square Preprint. 2021 Jul.|Research Square Preprint. 2023 Dec 1.|Research Square Preprint. 2023 Jul 25.|Research Square Preprint. July 21st, 2022.|Research Square Print. 2022 Aug.|Research Square Print. 2022 Jun.|Research Square Print. December 14th, 2022.|Sci Adv. 2025 Aug;11 (31) :eadu4270. |Sci Rep. 2024 Nov 4;14 (1) :26583.|Sci Total Environ. 2024 Jul 30:949:175139.|Sci Total Environ. 2024 May 10:933:173079.|Signal Transduct Target Ther. 2023 Mar 15;8 (1) :107.|SSRN. 2024 Jan 9.|Theranostics. 2021 Jan 19;11 (7) :3392-3416.|Vaccines. 2019 Dec 14;7 (4) :216.|Vet Parasitol. 2022 May;305:109710.|Vet Res. 2024 Jul 29;55 (1) :93.|Vet Sci. 2024 May 8;11 (5) :204.|Exp Neurol. 2024 Jul:377:114794.|Sci Transl Med. 2025 May 7;17 (797) :eads2694.